Method
The scientific basis of this atlas is Physiological Hazards of Combining Dextromethorphan with Other Substances . Study sources .
PHI
PHI is a provisional hazard rating for a combination with DXM on a 0–10 scale. A higher number means greater hazard. Confidence in the exact rating boundaries is low; clinical validation remains outstanding. The rating applies to the conditions stated in the combination’s description. PHI cannot be used to calculate the probability of a specific complication, a dose or a waiting period. Overlapping PHI ranges prevent reliable ranking of which combination is more hazardous.
Calling a severe outcome almost inevitable requires data on outcome frequency in people under defined, comparable conditions. Warnings, individual poisoning cases and plausible mechanisms are considered against this requirement.
PHI color scale
- 0
- 1–2
- 3–4
- 5–6
- 7–8
- 9
- 10
Color shows position on the PHI 0–10 scale. Exact numbers and range endpoints are given alongside it. Unrated combinations have their own status.
| PHI | Interpretation in this review |
|---|---|
| 0 | Demonstrated absence of a substantial additional hazard under specified conditions; not assigned to any combination |
| 1–2 | Small expected additional physiological hazard; evidence of safety may still be absent |
| 3–4 | Meaningful amplification of adverse effects or functional impairment; serious consequences are possible under unfavorable conditions |
| 5–6 | Substantial interaction with a plausible risk of a clinically significant complication |
| 7–8 | High concern because of multiple mechanisms or the potential for severe poisoning |
| 9 | Highest concern and strong grounds to avoid the combination, including contraindications or a closely relevant mechanism of severe toxicity |
| 10 | Reserved for evidence of an almost inevitable catastrophic outcome under defined conditions; not assigned |
Ranges reflect heterogeneous conditions and uncertainty in the assessment. They are not confidence intervals. Adjacent scores express a qualitative difference in judgments. They cannot be used to calculate a risk ratio. The index considers the physiological hazards of the whole combination while identifying the contribution of the interaction. The second substance’s own toxicity and its interaction with DXM are described as different components of hazard.
Confidence in the exact numerical boundaries of all ratings is Low; mechanism confidence cannot validate an ordinal score.
How well is this understood?
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
For some explanations, the type of evidence has not been classified. Their links lead to the review.
AUC is the area under the graph of blood concentration over time. Cmax is the highest measured concentration. DXO is dextrorphan, an active product of DXM breakdown. These measures describe drug concentration and metabolism.
Symbols beside the confidence assessment
Measurements of drug concentration or metabolism.Overdose data; they do not show outcome frequency at ordinary exposures.The study did not find the effect it tested for.Rating conditions
What limits this finding?
The site draws on studies, clinical reports and medicine prescribing information. Some sources were available only as abstracts. A finding needs to be read together with what was measured and the study conditions.
The historical section pairs older FAQ statements with current commentary. Sources and conditions for current conclusions appear beside the relevant text.
Scientific review: 9. Exclusions, repeated use, and limits of extrapolation
Terms
Reuptake
Return of a released neurotransmitter into a cell through a transporter protein.
Allows neurotransmitter recycling.
Sources: Reuptake
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
Neurotransmitter release
Movement of neurotransmitter molecules from a nerve ending into the space between cells.
During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.
Sources: Neurotransmitter release
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
Enzyme
A protein that helps chemical transformations in cells.
A transformation can build or break down a substance.
Sources: Enzyme
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
MAO — monoamine oxidase
An enzyme involved in breaking down serotonin.
Breakdown and reuptake are different processes.
Sources: MAO — monoamine oxidase
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
NMDA receptor
A glutamate receptor that controls an ion channel in a cell.
An ion channel lets electrically charged particles pass.
Sources: NMDA receptor
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
GABA
A neurotransmitter associated with inhibiting nerve-cell activity.
GABA-A and GABA-B are different receptor types.
Sources: GABA
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
CYP
A family of enzymes involved in chemically transforming drugs.
Metabolism can reduce or increase a substance’s activity.
Sources: CYP
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
Receptor
A protein that binds particular molecules and participates in a cell response.
Different receptors have different functions.
Sources: Receptor
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
SERT
A transporter protein involved in serotonin reuptake.
Inhibiting transport differs from acting on receptors.
Sources: SERT
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
KOR — κ-opioid receptor
One type of opioid receptor.
κ and μ are labels for different types of opioid receptor.
Sources: KOR — κ-opioid receptor
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
Pharmacokinetics (PK)
Study of how the body absorbs, distributes and eliminates a substance.
This includes concentration changes over time.
Sources: Pharmacokinetics (PK)
- IUPHAR Pharmacology Education Project: Clinical pharmacokinetics · Live page accessed 2026-10-12; revision label unavailable
Metabolite
A substance formed when another substance is chemically transformed in the body.
Some transformation products retain pharmacological activity.
Sources: Metabolite
- IUPHAR Pharmacology Education Project: Clinical pharmacokinetics · Live page accessed 2026-10-12; revision label unavailable
Autonomic nervous system
The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.
The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.
Sources: Autonomic nervous system
- Anatomy and Physiology 2e, §15.1 Divisions of the Autonomic Nervous System · Second edition; book publication date 20 April 2022. No separately verified webpage revision date.
Neurotransmitter
A substance that a nerve cell releases to send a chemical signal to another cell.
Receptors on the receiving cell respond to the signal. This is one way nerve cells communicate.
Sources: Neurotransmitter
- OpenStax: Neural Communication · Introduction to Behavioral Neuroscience, published 2024-11-13
Serotonin
A neurotransmitter: a substance that carries a chemical signal from a nerve cell.
There are different serotonin receptors in the brain and other parts of the body. The response to the signal depends on the receptor and its location.
Sources: Serotonin
- OpenStax: Neural Communication · Introduction to Behavioral Neuroscience, published 2024-11-13
- OpenStax: Neurotransmitters Made from Amino Acids — Serotonin · Introduction to Behavioral Neuroscience, published 2024-11-13
MAO-A
A form of the MAO enzyme involved in breaking down some chemical messengers, including serotonin.
These messengers are monoamines. MAO-A and MAO-B are two different forms of monoamine oxidase.
Sources: MAO-A
- MedlinePlus Genetics: MAOA gene — Normal Function · Page last updated 2017-05-01; accessed 2026-10-13
- Edmondson, Binda, Mattevi: Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B · Arch Biochem Biophys. 2007;464(2):269–276; DOI 10.1016/j.abb.2007.05.006; PMID 17573034
MAO-B
A form of the MAO enzyme involved in breaking down some chemical messengers in the monoamine group.
MAO-A and MAO-B are two different forms of monoamine oxidase. The letter B identifies the enzyme form.
Sources: MAO-B
- Edmondson, Binda, Mattevi: Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B · Arch Biochem Biophys. 2007;464(2):269–276; DOI 10.1016/j.abb.2007.05.006; PMID 17573034
CYP3A
A group of related CYP enzymes involved in the chemical transformation of medicines.
CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.
Sources: CYP3A
- Daly: Significance of the minor cytochrome P450 3A isoforms · Clin Pharmacokinet. 2006;45(1):13–31; DOI 10.2165/00003088-200645010-00002; PMID 16430309
QT interval
The time interval between the Q and T waves on an ECG recording of the heart’s electrical activity.
It reflects the electrical activity of the ventricles, the heart’s lower chambers.
Sources: QT interval
- NHLBI: Arrhythmias — Long QT Syndrome, What is long QT syndrome? · Live official page accessed 2026-10-13; separate page revision date not verified
Drug metabolism
Chemical transformation of a medicine in the body.
The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.
Sources: Drug metabolism
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
Metabolic activation
Transformation of an inactive precursor into an active drug in the body.
Further explanation
Activation here describes the substance produced by metabolism.
Sources: Metabolic activation
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
AUC
Area under the graph of a drug’s plasma concentration over time.
It combines concentration and time to describe drug exposure over an interval.
Sources: AUC
- Canadian Society of Pharmacology and Therapeutics: AUC · Live institutional page read 2026-10-13; separate revision label unavailable
Cmax
The highest drug concentration in plasma on a concentration–time curve.
It describes the peak concentration. AUC describes the area under the curve.
Sources: Cmax
- Canadian Society of Pharmacology and Therapeutics: concentration-time curve · Live institutional page read 2026-10-13; separate revision label unavailable
- Canadian Society of Pharmacology and Therapeutics: AUC · Live institutional page read 2026-10-13; separate revision label unavailable
Drug exposure
Description of how much of a medicine is present in the body, using its concentrations.
Cmax describes the concentration peak; AUC combines concentrations over time.
Sources: Drug exposure
- FDA: Examples of Drugs that Interact with CYP Enzymes and Transporter Systems · Live institutional page read 2026-10-13; separate revision label unavailable
Opioid
A drug that acts by binding to opioid receptors.
These receptors are found in the nervous system and other organs.
Sources: Opioid
- NCI Dictionary of Cancer Terms: opioid · Live institutional page read 2026-10-13; separate revision label unavailable
Sedation
A drug-induced state of calmness, relaxation or sleepiness.
Sources: Sedation
- NCI Dictionary of Cancer Terms: sedation · Live institutional page read 2026-10-13; separate revision label unavailable
Hypoxia
Reduced oxygen supply to a tissue.
Sources: Hypoxia
- NCI Dictionary of Cancer Terms: hypoxia · Live institutional page read 2026-10-13; separate revision label unavailable
Antimuscarinic action
Blocking the action of acetylcholine at muscarinic receptors.
Muscarinic receptors are one type of receptor for acetylcholine, a chemical messenger.
Sources: Antimuscarinic action
- IUPHAR PEP: The Parasympathetic Nervous System · Live institutional page read 2026-10-13; separate revision label unavailable
Adrenergic signaling
Signaling in which noradrenaline or adrenaline acts on adrenergic receptors.
The response depends on the receptor type and its location.
Sources: Adrenergic signaling
- IUPHAR PEP: The Sympathetic Nervous System · Live institutional page read 2026-10-13; separate revision label unavailable
GABA-A receptor
A receptor for GABA that forms an ion channel in the cell membrane.
It differs from the GABA-B receptor, which signals through a G protein.
Sources: GABA-A receptor
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
GABA-B receptor
A receptor for GABA that signals through a G protein inside the cell.
It differs from the GABA-A receptor, which forms an ion channel.
Sources: GABA-B receptor
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
Ischemia
Insufficient blood supply to part of the body.
A lack of oxygen and nutrients can damage the tissue.
Sources: Ischemia
- NCI Dictionary of Cancer Terms: ischemia · Official online entry read 2026-10-13; no update date shown in the retrieved entry
Arrhythmia
A disturbance of the heart’s rate or rhythm.
The heart can beat too fast, too slowly or irregularly.
Sources: Arrhythmia
- NHLBI: Arrhythmias — What Is an Arrhythmia? · Last updated March 24, 2022; retrieved 2026-10-13
Vitamin B12
A vitamin that helps keep blood and nerve cells healthy.
It also helps make DNA, the cells’ genetic material.
Sources: Vitamin B12
- NIH ODS: Vitamin B12 — Fact Sheet for Consumers · Updated December 15, 2023; retrieved 2026-10-13
Monoamines
A group of substances formed in living organisms; several act as chemical messengers between nerve cells.
Examples include serotonin, dopamine and norepinephrine.
Sources: Monoamines
- NLM MeSH: Biogenic Monoamines (D015306) · Live MeSH entry read 2026-10-13; year introduced 1989; no separate visible revision date
- OpenStax Anatomy and Physiology 2e, 12.5 Communication Between Neurons · Second edition; online section read 2026-10-13
Catecholamines
A group of chemical messengers made by nerve cells.
Examples are dopamine, adrenaline and noradrenaline.
Sources: Catecholamines
- NCI Dictionary of Cancer Terms: catecholamine · Complete live entry read 2026-10-13; no visible update date
Pharmacodynamics
The study of a drug’s effects on the body.
This includes its beneficial and harmful effects.
Sources: Pharmacodynamics
- IUPHAR PEP Glossary: pharmacodynamics · Live institutional glossary read 2026-10-13; separate entry revision unavailable
Dissociation
A sense of disconnection between thoughts, memory and one’s sense of self.
One form involves feeling detached from the surrounding people, places or objects.
Sources: Dissociation
- NIMH: Feelings of Detachment After Trauma May Signal Worse Mental Health Outcomes · June 24, 2022; page marked Archived Content, read 2026-10-13
Airway protective reflexes
Reflex actions that help protect the airways.
Coughing and swallowing are examples; they work in a coordinated way.
Sources: Airway protective reflexes
- Pitts T. Airway protective mechanisms. Lung 192(1):27–31 (2014) · 2014 Feb; online 2013 Dec 3; PMID 24297325; DOI 10.1007/s00408-013-9540-y
Hepatotoxicity
Liver injury caused by a toxic substance.
Possible sources include medicines, chemicals, herbal products and dietary supplements.
Sources: Hepatotoxicity
- NIH NIDDK LiverTox: Glossary, hepatotoxicity · Bookshelf NBK548773 PDF, page 4 of 8; retrieved 2026-10-13; separate entry revision unavailable
Systemic effects
Effects occurring away from the place where a substance enters the body.
The substance is absorbed and distributed through the body.
Sources: Systemic effects
- US EPA Terminology Services: Drinking Water Technical & Legal Terms, Systemic Effects · Catalog last update February 17, 2009; retrieved 2026-10-13
Neuroprotection
Processes that help prevent injury and degeneration of nerve cells in the central nervous system.
Further explanation
The name describes protection of nerve cells.
Sources: Neuroprotection
- NLM MeSH: Neuroprotection (D000066829) · Live official entry read 2026-10-13; year introduced 2016; separate revision date unavailable
Olney’s lesions (rat experiments)
Changes in nerve cells of the brain’s cortex described in adult-rat experiments involving NMDA receptor blockade.
Small cavities, called vacuoles, appear within the cells; these changes can be reversible.
Sources: Olney’s lesions (rat experiments)
- Bifari et al. (2022), REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats · Frontiers in Pharmacology 13:863959; published 25 April 2022; DOI 10.3389/fphar.2022.863959
Extrapolation
Using information from studied groups, conditions or products to draw conclusions about other groups, conditions or products.
This relies on assumptions about how the studied and new situations are related.
Sources: Extrapolation
- EMA Reflection paper on the use of extrapolation in the development of medicines for paediatrics, Final · EMA/189724/2018; cover dated 7 October 2018, final CHMP adoption listed as 17 October 2018
Demethylation
A chemical change that removes one or more methyl groups from a compound.
A methyl group contains one carbon atom and three hydrogen atoms.
Sources: Demethylation
- NLM MedGen: Demethylation (C0598864) · Live official entry read 2026-10-13; definition attributed to MeSH; separate revision date unavailable
- NCI Dictionary of Cancer Terms: methyl group · Complete live entry read 2026-10-13; no visible update date
Recovery half-life
A measure of how quickly enzyme activity recovers, calculated from changes in an activity marker over time.
In an exponential model, the recovery half-life is the time for a falling marker to halve. The marker can be the ratio of a test substance to its breakdown product.
Sources: Recovery half-life
- O’Mathúna et al.: CYP2D6 recovery — Data Analysis · Journal of Clinical Psychopharmacology 28(5), 523–529 (2008); publisher PDF printed 525–531; selected printed PDF pages 528–529
Serotonin toxicity
A condition caused by excessive serotonin activity in the nervous system.
Also called serotonin syndrome. Features can include tremor and involuntary muscle jerks, raised body temperature, a fast heartbeat, agitation or confusion.
Sources: Serotonin toxicity
- Ables and Nagubilli: Prevention, Diagnosis, and Management of Serotonin Syndrome · American Family Physician 81(9), 1139–1142 (2010)
- Chiew and Isbister: Management of serotonin syndrome (toxicity) · British Journal of Clinical Pharmacology 91(3), 654–661 (2025); first published 26 June 2024; DOI 10.1111/bcp.16152
Additive effects
A combined effect that matches the expected addition of the substances’ actions.
This is called additivity. The expected result is calculated from each substance’s action on its own, using the same measured effect and a chosen model of addition.
Sources: Additive effects
- IUPAC: Glossary for chemists of terms used in toxicology — additive effect · IUPAC Recommendations 1993; Pure and Applied Chemistry 65(9), 2003–2122
- Roell, Reif and Motsinger-Reif: An Introduction to Terminology and Methodology of Chemical Synergy · Frontiers in Pharmacology 8:158 (20 April 2017); DOI 10.3389/fphar.2017.00158
Synergy
A combined effect that is stronger than expected from additivity.
Synergy is assessed by comparing the measured combined effect with the result predicted from the substances’ separate actions. The comparison uses a specified effect and a chosen model of additivity.
Sources: Synergy
- Roell, Reif and Motsinger-Reif: An Introduction to Terminology and Methodology of Chemical Synergy · Frontiers in Pharmacology 8:158 (20 April 2017); DOI 10.3389/fphar.2017.00158
MAO-B selectivity
Preferential inhibition of the MAO-B form of the enzyme compared with MAO-A.
MAO-A and MAO-B are two forms of monoamine oxidase. Loss of selectivity means more pronounced inhibition of MAO-A.
Sources: MAO-B selectivity
- Merck Manual Professional: Drug–Receptor Interactions — selectivity · Full review June 2025; Abimbola Farinde; peer reviewed by Eva M. Vivian
- EMSAM U.S. prescribing information — MAO isoenzymes and selectivity · U.S. prescribing information revised May 2020; section 12.2
Sympathomimetic decongestants
Medicines that relieve a blocked nose by narrowing blood vessels in its lining.
They mimic effects of the sympathetic nervous system. Narrowing these vessels reduces swelling of the nasal lining and helps air pass through.
Sources: Sympathomimetic decongestants
- NHS: Decongestants · Online medicines reference; page last reviewed 3 November 2022
- NLM MeSH: Nasal Decongestants · MeSH Descriptor Data 2026, D014663; Scope Note
- NLM MeSH: Sympathomimetics · MeSH Descriptor Data 2026, D013566; Scope Note
Alkaloids
A group of nitrogen-containing substances found in plants and some fungi.
Alkaloids are also made in the laboratory. Caffeine and nicotine are examples of this group.
Sources: Alkaloids
- NCI Dictionary of Cancer Terms: Alkaloid · Undated online dictionary entry, accessed 16 October 2026
Ceiling effect
The greatest response attainable for a particular effect of a substance.
Near this limit, increasing the dose produces progressively smaller gains in the effect. Each measured effect has its own dose–response relationship.
Sources: Ceiling effect
- Merck Manual Professional: Dose-Response Relationships · Full review June 2025; updated July 2026; Abimbola Farinde
- IUPHAR Pharmacology Education Project: Pharmacodynamics · Undated online teaching resource; dose-response relationship and therapeutic index sections
Educational material. Remember that each person's body is unique.